Cover Image

A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson’s disease, in healthy volunteers

Wonsuk Shin,1 Kyoung Soo Lim,1 Min-Kyoung Kim,1 Hyun Sook Kim,2 Jihwa Hong,3 Stanford Jhee,3 Joseph Kim,3 Sungeun Yoo,4 Yeon-Tae Chung,4 Jae Moon Lee,4 Doo-Yeoun Cho1 1Department of Clinical Pharmacology and Therapeutics, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Repub...

Full description

Saved in:

Bibliographic Details
Main Authors:	Shin W (Author), Lim KS (Author), Kim MK (Author), Kim HS (Author), Hong J (Author), Jhee S (Author), Kim J (Author), Yoo S (Author), Chung YT (Author), Lee JM (Author), Cho DY (Author)
Format:	Book
Published:	Dove Medical Press, 2019-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Pharmacokinetic interactions and tolerability of rosuvastatin and ezetimibe: an open-label, randomized, multiple-dose, crossover study in healthy male volunteers
by: Kim H, et al.
Published: (2018)

Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects
by: Cha YJ, et al.
Published: (2014)

First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of a Neuroprotective Poly (ADP‐ribose) Polymerase‐1 Inhibitor, JPI-289, in Healthy Volunteers
by: Han S, et al.
Published: (2020)

Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers
by: Choi C, et al.
Published: (2018)

Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers
by: Gu N, et al.
Published: (2014)

Single and multiple dose pharmacokinetics and tolerability of HX-1171, a novel antioxidant, in healthy volunteers
by: Kim YH, et al.
Published: (2015)

Phase 1 study to access safety, tolerability, pharmacokinetics, and pharmacodynamics of kynurenine in healthy volunteers
by: Mohammad Al‐Mahdi Al‐Karagholi, et al.
Published: (2021)

Evaluation of the pharmacokinetic and pharmacodynamic drug interactions between cilnidipine and valsartan, in healthy volunteers
by: Lee J, et al.
Published: (2014)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers
by: David Monteith, et al.
Published: (2017)

Scientific American Supplement No. 819, September 12, 1891
by: Various

Pharmacokinetic and pharmacodynamic drug-drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers
by: Dasohm Kim, et al.
Published: (2023)

Pharmacokinetics, pharmacodynamics, safety and tolerability of cilofexor, a novel nonsteroidal Farnesoid X receptor agonist, in healthy volunteers
by: Islam R. Younis, et al.
Published: (2023)

Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers
by: Deok Y. Yoon, et al.
Published: (2021)

Safety, tolerability, pharmacokinetics, and pharmacodynamics of a TLR7 agonist prodrug RO6870868 in healthy volunteers
by: Joseph F. Grippo, et al.
Published: (2021)

A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects
by: Park SI, et al.
Published: (2015)

Pharmacokinetics and tolerability of IDP-73152 mesylate after a single oral administration under fasted and fed conditions in healthy volunteers
by: Shin D, et al.
Published: (2019)

Safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of vutiglabridin: A first‐in‐class, first‐in‐human study
by: Joo Young Na, et al.
Published: (2022)

Single dose pharmacokinetics of the novel transdermal donepezil patch in healthy volunteers
by: Kim YH, et al.
Published: (2015)

Evaluation of Tolerability, Pharmacokinetics and Pharmacodynamics of Vicagrel, a Novel P2Y12 Antagonist, in Healthy Chinese Volunteers
by: Xiaojiao Li, et al.
Published: (2018)

A randomized, placebo‐controlled first‐in‐human study of oral TQS‐168 in healthy volunteers: Assessment of safety, tolerability, pharmacokinetics, pharmacodynamics, and food effect
by: Jonas Hannestad, et al.
Published: (2024)

Study of GABA in healthy volunteers: pharmacokinetics and pharmacodynamics
by: Junfeng eLi, et al.
Published: (2015)

The health benefits of volunteering at a free, weekly, 5 km event in the UK: A cross-sectional study of volunteers at parkrun
by: Steve Haake, et al.
Published: (2022)

The health benefits of volunteering at a free, weekly, 5 km event in the UK: A cross-sectional study of volunteers at parkrun.
by: Steve Haake, et al.
Published: (2022)

Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin and Pioglitazone in Healthy Male Subjects
by: Hwang I, et al.
Published: (2020)

Fas/FasL promoter gene polymorphism in patients with rheumatoid arthritis
by: A. Berdeli, et al.
Published: (2012)

A first-in-human, double-blind, placebo-controlled, randomized, dose escalation study of DWP05195, a novel TRPV1 antagonist, in healthy volunteers
by: Lee J, et al.
Published: (2017)

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteers
by: Marie A. Printz, BA, et al.
Published: (2020)

The CTLA4 -819 C/T Dimorphism Is Associated with Type 1 Diabetes in Egyptian Children
by: HM Saleh, et al.
Published: (2009)

The CTLA4 -819 C/T Dimorphism Is Associated with Type 1 Diabetes in Egyptian Children
by: HM Saleh, et al.
Published: (2009)

Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects
by: Sidharta PN, et al.
Published: (2019)

Expression of Fas antigen and Fas ligand in bronchoalveolar lavage from silicosis patients
by: Agnès Hamzaoui, et al.
Published: (2003)

Comprehensive Assessment of Pharmacokinetics, Pharmacodynamics, and Tolerability of Ligelizumab in Healthy Volunteers and Patients with Chronic Spontaneous Urticaria to Optimize Its Subcutaneous Delivery System
by: Yan Ji, et al.
Published: (2023)

Pharmacokinetic interaction between udenafil and dapoxetine: a randomized, open-labeled crossover study in healthy male volunteers
by: Kim YH, et al.
Published: (2015)

Pharmacokinetic Evaluation by Modeling and Simulation Analysis of a Donepezil Patch Formulation in Healthy Male Volunteers
by: Yoon SK, et al.
Published: (2020)

Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects
by: Yoon S, et al.
Published: (2015)

Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers
by: Desmond Y. H. Yap, et al.
Published: (2021)

Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers
by: Nagelschmitz J, et al.
Published: (2014)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cholic Acid (MT921) after a Subcutaneous Injection in the Submental Area to Humans
by: Hyewon Chung, et al.
Published: (2021)

Effects of renal function on pharmacokinetics and pharmacodynamics of lesinurad in adult volunteers
by: Gillen M, et al.
Published: (2016)

Population Pharmacokinetics and Pharmacodynamics of Benralizumab in Healthy Volunteers and Patients With Asthma
by: B Wang, et al.
Published: (2017)